Entadfi
Product Images NDC 69681-125
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Entadfi (NDC 69681-125). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Veru Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image Of Bottle Label (5 mg/5 mg)
Image Of Chemical Structure Of Tadalafil (Cs1)
Image Of Chemical Structure Of Finasteride (Cs2)
Image Of Mean Maximal Change In Blood Pressure (tadalafil Minus Placebo, Point Estimate With 90% Ci) In Response To Sublingual Nitroglycerin At 2 (supine Only), 4, 8, 24, 48, 72, And 96 Hours After The Last Dose Of Tadalafil 20 mg Or Placebo (Fig1)
Image Of Doxazosin Study 1: Mean Change From Baseline In Systolic Blood Pressure (Fig2)
The text is describing a study that involves two groups of participants: one group taking Tadalafil 20mg and Doxazosin 8mg, and another group taking Placebo and Doxazosin 8mg. The study measures Supine Systolic BP (blood pressure in mmHg) over a period of time (6 to 18 hours post-dose) for both groups.*
Image Of Doxazosin Study 2 (part C): Mean Change From Time-matched Baseline In Systolic Blood Pressure (Fig3)
Image Of Mean Total Ipss Changes By Visit In Bph Patients Taking Tadalafil Together With Finasteride (Fig4)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.